Neuroradiology: Page 198

Molecular Insight launches new Azedra trials
By AuntMinnie.com staff writers
Molecular Insight Pharmaceuticals of Cambridge, MA, has initiated a phase II clinical trial of Azedra, a small-molecule targeted radiotherapeutic agent for the treatment of children with neuroblastoma, the company said.
April 30, 2008
IMRIS receives Oregon order
By AuntMinnie.com staff writers
Canadian intraoperative MRI developer IMRIS has sold its IMRISneuro neurosurgical imaging system to Providence St. Vincent Medical Center in Portland, OR.
April 27, 2008
Dual-energy CT offers two approaches for CTA bone removal
By Rob Skelding
The ability to depict blood vessels accurately within a bony environment is vital to the correct diagnosis of intracranial vascular pathologies. However, a weakness of conventional CT angiography (CTA) is its limited capacity to depict aneurysms and stenoses located at the skull base, close to the bone. A pair of recent studies looks at the effectiveness of two new techniques using dual-energy CT for bone removal.
April 22, 2008
2008 04 24 10 16 24 706
NeuroLogica buys xenon CT perfusion technology
By AuntMinnie.com staff writers
Portable CT developer NeuroLogica said it has acquired all xenon CT perfusion (XeCT) technology assets from Diversified Diagnostic Products of Houston.
April 22, 2008
Diffusion-mapping MRI predicts radiation therapy response
By Barbara Boughton
In one of the largest prospective clinical trials to date, researchers at the University of Michigan in Ann Arbor have found that functional diffusion-mapping MRI can provide an earlier assessment of response to radiation therapy treatment for glioma patients than traditional MRI. The researchers presented the study at the 2008 American Association for Cancer Research (AACR) meeting in San Diego.
April 21, 2008
NordicNeuroLab forms U.S. office
By AuntMinnie.com staff writers
Norwegian functional MRI developer NordicNeuroLab has opened a U.S. office in Milwaukee.
April 15, 2008
FluoroPharma licenses MGH PET agents
By AuntMinnie.com staff writers
Imaging agent developer FluoroPharma of Boston has signed an agreement with Massachusetts General Hospital (MGH), also of Boston, for the development and commercialization of PET agents for diagnosing Alzheimer's disease and monitoring treatment.
March 26, 2008
3D ultrasound can improve life for sonographers, save money
By Erik L. Ridley
SAN DIEGO - A growing body of research continues to advance the clinical and efficiency benefits of 3D ultrasound, but the technology may also offer a means of addressing the painful and costly issue of repetitive stress injuries in sonographers, according to a pair of studies presented at the recent 2008 American Institute of Ultrasound in Medicine (AIUM) meeting.
March 17, 2008
Siemens adds Definition applications
By AuntMinnie.com staff writers
Siemens Medical Solutions has received U.S. Food and Drug Administration 510(k) clearance for four applications on its Somatom Definition dual-source CT scanner.
March 10, 2008
Part II: Modalities, input, and image processing see stroke differently
By Eric Barnes
Our two-part series on acute stroke imaging looks at current controversies in imaging and treating ischemic stroke patients. In the final installment, CT perfusion pioneer Dr. Max Wintermark examines differences in imaging representations of infarcted brain tissue -- and a plan for addressing the challenges.
March 2, 2008
2008 02 26 16 39 57 706
Inversion-recovery MRI falls short in brain tumor detection
By Shalmali Pal
Inversion-recovery (IR) imaging has made significant strides in brain MR, offering higher T1-weighted contrast and improving the contrast ratio of tumor to white matter. But IR imaging still cannot best spin-echo (SE) MRI for detecting brain metastases, according to radiologists from China. They compared the two MR protocols in 31 patients treated at the First Affiliated Hospital of Anhui Medical University in Hefei.
February 26, 2008
Isotope shows promise in brain cancer treatment
By Wayne Forrest
Researchers from the Duke University Medical Center in Durham, NC, are heralding early success with the isotope astatine-211 (At-211) in destroying residual cancer cells in the brain, while sparing healthy cells, and extending the lives of cancer patients. The therapy shows promising results for treating recurrent brain tumors and other cancers.
February 21, 2008
2008 02 21 16 12 03 706
Previous Page
Page 198 of 239
Next Page